CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients

CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients

Da: GRACEcast
0 0 6 anni fa
Dr. Heather Wakelee of Stanford University Medical Center talks about a drug still in development for EGFR lung cancer patients, CO-1686. February 2014.

Seguici su Facebook